Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 53 articles: HTML format

Single Articles

August 2020
1. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
   Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
   J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
   PubMed     Abstract available
   
   
   April 2020
2. ZAMARIN D, Burger RA, Sill MW, Powell DJ Jr, et al
   Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
   J Clin Oncol. 2020 Apr 10:JCO1902059. doi: 10.1200/JCO.19.02059.
   PubMed     Abstract available
   
   
   February 2020
3. PENSON RT, Valencia RV, Cibula D, Colombo N, et al
   Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
   J Clin Oncol. 2020 Feb 19:JCO1902745. doi: 10.1200/JCO.19.02745.
   PubMed     Abstract available
   
   
   January 2020
4. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
   Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
   J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
   PubMed     Abstract available
   
   
   
5. TEWARI KS, Monk BJ, Burger RA
   Reply to Farolfi et al and Haines et al.
   J Clin Oncol. 2020;38:173-174.
   PubMed    
   
   
   November 2019
6. HAINES IE, Gabor Miklos GL
   Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.
   J Clin Oncol. 2019 Nov 7:JCO1901912. doi: 10.1200/JCO.19.01912.
   PubMed    
   
   
   
7. FAROLFI A, Lorusso D, Pignata S, De Giorgi U, et al
   Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
   J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055.
   PubMed    
   
   
   September 2019
8. DE JAEGHERE EA, Gremonprez FB, Tummers PG, Willaert WC, et al
   Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
   J Clin Oncol. 2019 Sep 25:JCO1901179. doi: 10.1200/JCO.19.01179.
   PubMed    
   
   
   
9. TOMAO F, Benedetti Panici P, Tomao S
   Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.
   J Clin Oncol. 2019 Sep 25:JCO1901163. doi: 10.1200/JCO.19.01163.
   PubMed    
   
   
   
10. MATULONIS UA, Walder L, Nottrup TJ, Bessette P, et al
    Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917.
    PubMed     Abstract available
    
    
    August 2019
11. BUCKANOVICH RJ, Rustin G, Uppal S, Olawaiye AB, et al
    No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
    J Clin Oncol. 2019 Aug 26:JCO1901650. doi: 10.1200/JCO.19.01650.
    PubMed    
    
    
    
12. VERGOTE I, Harter P, Chiva L
    Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?
    J Clin Oncol. 2019 Aug 12:JCO1900091. doi: 10.1200/JCO.19.00091.
    PubMed    
    
    
    
13. PUJADE-LAURAINE E, Banerjee S, Pignata S
    Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
    J Clin Oncol. 2019 Aug 12:JCO1900194. doi: 10.1200/JCO.19.00194.
    PubMed    
    
    
    
14. GERSHENSON DM, Okamoto A, Ray-Coquard I
    Management of Rare Ovarian Cancer Histologies.
    J Clin Oncol. 2019 Aug 12:JCO1802419. doi: 10.1200/JCO.18.02419.
    PubMed    
    
    
    
15. DU BOIS A, Baert T, Vergote I
    Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900022. doi: 10.1200/JCO.19.00022.
    PubMed    
    
    
    
16. ARMSTRONG DK, Walker JL
    Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900671. doi: 10.1200/JCO.19.00671.
    PubMed    
    
    
    
17. BOUBERHAN S, Pujade-Lauraine E, Cannistra SA
    Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900314. doi: 10.1200/JCO.19.00314.
    PubMed    
    
    
    
18. GOURLEY C, Bookman MA
    Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900337. doi: 10.1200/JCO.19.00337.
    PubMed    
    
    
    
19. KANDALAFT LE, Odunsi K, Coukos G
    Immunotherapy in Ovarian Cancer: Are We There Yet?
    J Clin Oncol. 2019 Aug 12:JCO1900508. doi: 10.1200/JCO.19.00508.
    PubMed    
    
    
    June 2019
20. KOOLE SN, van Lieshout C, van Driel WJ, van Schagen E, et al
    Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
    J Clin Oncol. 2019 Jun 28:JCO1900594. doi: 10.1200/JCO.19.00594.
    PubMed     Abstract available
    
    
    
21. TEWARI KS, Burger RA, Enserro D, Norquist BM, et al
    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009.
    PubMed     Abstract available
    
    
    
22. DEL CAMPO JM, Matulonis UA, Malander S, Provencher D, et al
    Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238.
    PubMed     Abstract available
    
    
    April 2019
23. BOUBERHAN S, Shea M, Cannistra SA
    Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
    J Clin Oncol. 2019 Apr 19:JCO1900500. doi: 10.1200/JCO.19.00500.
    PubMed     Abstract available
    
    
    
24. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available
    
    
    
25. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    PubMed     Abstract available
    
    
    February 2019
26. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    PubMed     Abstract available
    
    
    January 2019
27. BOULAY RM
    The Boy I Never Knew.
    J Clin Oncol. 2019;37:254-255.
    PubMed    
    
    
    March 2018
28. COLOMBO N, Huang G, Scambia G, Chalas E, et al
    Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    J Clin Oncol. 2018 Mar 20:JCO2017762781. doi: 10.1200/JCO.2017.76.2781.
    PubMed     Abstract available
    
    
    October 2017
29. BERCHUCK A, Secord AA, Moss HA, Havrilesky LJ, et al
    Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    J Clin Oncol. 2017 Oct 26:JCO2017745752. doi: 10.1200/JCO.2017.74.5752.
    PubMed    
    
    
    August 2017
30. PIGNATA S, Scambia G, Bologna A, Signoriello S, et al
    Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    J Clin Oncol. 2017 Aug 21:JCO2017734293. doi: 10.1200/JCO.2017.73.4293.
    PubMed     Abstract available
    
    
    
31. CHILDERS CP, Childers KK, Maggard-Gibbons M, Macinko J, et al
    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
    J Clin Oncol. 2017 Aug 18:JCO2017736314. doi: 10.1200/JCO.2017.73.6314.
    PubMed     Abstract available
    
    
    July 2017
32. SAMIMI G, Bernardini MQ, Brody LC, Caga-Anan CF, et al
    Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
    J Clin Oncol. 2017;35:2329-2337.
    PubMed     Abstract available
    
    
    
33. WILLMANN JK, Bonomo L, Carla Testa A, Rinaldi P, et al
    Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.
    J Clin Oncol. 2017;35:2133-2140.
    PubMed     Abstract available
    
    
    May 2017
34. BERCHUCK A, Havrilesky LJ, Kauff ND
    Is There a Role for Ovarian Cancer Screening in High-Risk Women?
    J Clin Oncol. 2017;35:1384-1386.
    PubMed    
    
    
    April 2017
35. CHRISTIE EL, Fereday S, Doig K, Pattnaik S, et al
    Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    J Clin Oncol. 2017;35:1274-1280.
    PubMed     Abstract available
    
    
    
36. KONECNY GE
    Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
    J Clin Oncol. 2017;35:1151-1153.
    PubMed    
    
    
    
37. SHAIKH F, Cullen JW, Olson TA, Pashankar F, et al
    Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017;35:1203-1210.
    PubMed     Abstract available
    
    
    
38. LHEUREUX S, Bruce JP, Burnier JV, Karakasis K, et al
    Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    J Clin Oncol. 2017;35:1240-1249.
    PubMed     Abstract available
    
    
    
39. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    PubMed     Abstract available
    
    
    
40. GERSHENSON DM, Bodurka DC, Coleman RL, Lu KH, et al
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
    J Clin Oncol. 2017;35:1103-1111.
    PubMed     Abstract available
    
    
    
41. MOORE KN, Martin LP, O'Malley DM, Matulonis UA, et al
    Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    J Clin Oncol. 2017;35:1112-1118.
    PubMed     Abstract available
    
    
    February 2017
42. ROSENTHAL AN, Fraser LS, Philpott S, Manchanda R, et al
    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    J Clin Oncol. 2017 Feb 27:JCO2016699330. doi: 10.1200/JCO.2016.69.9330.
    PubMed     Abstract available
    
    
    January 2017
43. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.
    PubMed    
    
    
    December 2016
44. RUTTEN MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, et al
    Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Dec 28:JCO2016692962.
    PubMed     Abstract available
    
    
    
45. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.
    PubMed    
    
    
    
46. LIU JF, Ray-Coquard I, Selle F, Poveda AM, et al
    Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    J Clin Oncol. 2016;34:4345-4353.
    PubMed     Abstract available
    
    
    
47. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.
    PubMed    
    
    
    
48. LEIJEN S, van Geel RM, Sonke GS, de Jong D, et al
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    J Clin Oncol. 2016;34:4354-4361.
    PubMed     Abstract available
    
    
    March 2016
49. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    PubMed     Abstract available
    
    
    January 2016
50. HORN C, Campbell G, Hagan T, Bovbjerg DH, et al
    Associations between peripheral neuropathy and nausea/vomiting in survivors of ovarian cancer: Evidence of persistent vagal neuropathies?
    J Clin Oncol. 2016;34.
    PubMed     Abstract available
    
    
    
51. ANGARITA A, Cristello A, Lippitt M, Nickles Fader A, et al
    The "little big things": A qualitative study of ovarian cancer survivors and their experiences with the health care system.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available
    
    
    
52. GASPARRI ML, Crispino S, La Russa C, Marchetti C, et al
    A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: Elderly versus younger women.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available
    
    
    
53. BLACKMON JE, Recklitis CJ, Wright AA
    Preliminary results from the Sexual Therapy and Rehabilitation after Treatment for Ovarian Cancer (START-OC) study.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: